KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Other Operating Expenses (2018 - 2025)

Emergent BioSolutions has reported Other Operating Expenses over the past 10 years, most recently at -$12.2 million for Q1 2025.

  • For Q1 2025, Other Operating Expenses changed N/A year-over-year to -$12.2 million; the TTM value through Dec 2025 reached -$12.2 million, down 150.21%, while the annual FY2025 figure was -$12.2 million, 150.21% down from the prior year.
  • Other Operating Expenses for Q1 2025 was -$12.2 million at Emergent BioSolutions, down from $64.3 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $305.2 million in Q4 2021 and troughed at -$40.0 million in Q2 2024.
  • A 5-year average of $120.0 million and a median of $114.2 million in 2021 define the central range for Other Operating Expenses.
  • On a YoY basis, Other Operating Expenses climbed as much as 9285.71% in 2024 and fell as far as 153.4% in 2024.
  • Year by year, Other Operating Expenses stood at $305.2 million in 2021, then tumbled by 44.33% to $169.9 million in 2022, then crashed by 100.41% to -$700000.0 in 2023, then skyrocketed by 9285.71% to $64.3 million in 2024, then plummeted by 118.97% to -$12.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for EBS at -$12.2 million in Q1 2025, $64.3 million in Q3 2024, and -$40.0 million in Q2 2024.